文献速递中医内科中药与中成药合理使用

中药注射剂联合EGFR-TKI干预非小细胞肺癌的系统评价与Meta分析

Chinese herbal injections combined with EGFR-TKIs for intervention of non-small cell lung cancer: a systematic review and meta-analysis.
PubMed 文献 · Front Pharmacol · 2025-11-19

该系统评价与Meta分析纳入13项随机对照试验共899例晚期EGFR突变NSCLC患者,比较中药注射剂联合EGFR-TKI与单用EGFR-TKI的疗效与安全性。结果显示康莱特注射液提高客观缓解率,康莱特和艾迪注射液提高疾病控制率,生脉注射液减少皮肤毒性,联合治疗改善CD3+、CD4+及CD4+/CD8+比值,但多数结局证据质量低。

要点

  • 康莱特注射液联合EGFR-TKI可提高ORR(RR=1.52)和DCR(RR=1.14)。
  • 艾迪注射液联合EGFR-TKI可提高DCR(RR=1.23)。
  • 生脉注射液联合EGFR-TKI可减少皮肤毒性(RR=0.35)。

核心结论

  • 中药注射剂联合EGFR-TKI可改善NSCLC患者的ORR、DCR、不良反应及免疫功能。
  • 因纳入研究存在局限性,需高质量严谨设计的临床试验证实。

研究设计与样本

  • 系统评价与Meta分析,纳入13项比较中药注射剂联合EGFR-TKI与单用EGFR-TKI的随机对照试验,共899例受试者。
  • 使用Cochrane手册评估方法学质量,采用R 4.4.0和RevMan 5.4进行Meta分析,并使用GRADE方法评价证据质量。

主要发现

  • 康莱特注射液显著提高ORR(RR=1.52,95%CI 1.07-2.15,p=0.02)。
  • 康莱特注射液(RR=1.14,95%CI 1.01-1.29,p=0.04)和艾迪注射液(RR=1.23,95%CI 1.02-1.48,p=0.03)影响DCR。
  • 生脉注射液联合EGFR-TKI减少皮肤毒性(RR=0.35,95%CI 0.18-0.69,p=0.002)。
  • 联合治疗改善CD3+(SMD=1.38,95%CI 0.46-2.30,p=0.003)、CD4+(SMD=1.08,95%CI 0.51-1.65,p=0.0002)及CD4+/CD8+比值(SMD=0.96,95%CI 0.54-1.38,p<0.00001)。
  • GRADE方法显示多数结局为低确定性证据。

关键数值与推荐

  • 康莱特注射液联合EGFR-TKI的ORR:RR=1.52(95%CI 1.07-2.15,p=0.02)。
  • 康莱特注射液联合EGFR-TKI的DCR:RR=1.14(95%CI 1.01-1.29,p=0.04)。
  • 艾迪注射液联合EGFR-TKI的DCR:RR=1.23(95%CI 1.02-1.48,p=0.03)。
  • 生脉注射液联合EGFR-TKI的皮肤毒性:RR=0.35(95%CI 0.18-0.69,p=0.002)。
  • 联合治疗对CD3+、CD4+、CD4+/CD8+的SMD分别为1.38、1.08、0.96。

临床怎么用

  • 对晚期EGFR突变NSCLC患者,可考虑在EGFR-TKI基础上联合康莱特注射液以提高ORR和DCR。
  • 艾迪注射液联合EGFR-TKI可能提高DCR,生脉注射液联合可能减少皮肤毒性。
  • 联合中药注射剂可能改善免疫功能,但需结合低证据质量谨慎决策。

局限性

  • 多数结局的证据确定性为低级别。
  • 纳入研究存在局限性,需高质量临床试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To serve as a clinical reference, we conducted a meta-analysis to assess and compare the efficacy and safety of combining Chinese herbal injections (CHIs) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for treating advanced EGFR-mutated non-small cell lung cancer (NSCLC). METHODS: Predetermined databases contained randomized controlled studies comparing CHIs + EGFR-TKIs to EGFR-TKIs alone. The Cochrane Reviewer's Handbook for Systematic Reviews of Interventions was used to evaluate study methodology. To assess the effects of CHIs on patients with NSCLC receiving EGFR-TKIs, R (version 4.4.0) and RevMan (version 5.4) were used to conduct a meta-analysis using the Mantel-Haenszel or Inverse Variance method. The quality of results was evaluated using the Grade of Recommendations Assessment, Development and Evaluation (GRADE) method. RESULTS: The 13 qualifying trials included 899 subjects. The objective response rate (ORR) was significantly increased by Kanglaite injection (RR = 1.52, 95% confidence interval [CI]: 1.07-2.15, p = 0.02). The disease control rate (DCR) was influenced by Kanglaite injection (RR = 1.14, 95% CI: 1.01-1.29, p = 0.04) and Aidi injection (RR = 1.23, 95% CI: 1.02-1.48, p = 0.03). Shenmai injection + EGFR-TKIs reduced dermatologic toxicities (RR = 0.35, 95% CI: 0.18-0.69, p = 0.002). The combination of CHIs with EGFR-TKIs improved the expression of CD3+ (standardized mean difference [SMD] = 1.38, 95% CI: 0.46-2.30, p = 0.003), CD4+ (SMD = 1.08, 95% CI: 0.51-1.65, p = 0.0002), and the CD4+/CD8+ ratio (SMD = 0.96, 95% CI: 0.54-1.38, p < 0.00001) compared to EGFR-TKIs alone. The GRADE method revealed that most outcomes exhibited low certainty evidence. CONCLUSION: The combination of CHIs and EGFR-TKIs improved ORR, DCR, adverse effects, and immune function in patients with NSCLC. Due to limitations in the assessed research, high-quality clinical studies with rigorous designs are required to confirm the findings. SYSTEMATIC REVIEW: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024561845, Identifier CRD42024561845.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yuan Z, Yan M, Wu T, et al. Chinese herbal injections combined with EGFR-TKIs for intervention of non-small cell lung cancer: a systematic review and meta-analysis. Front Pharmacol. 2025. PMID: 41347160. doi:10.3389/fphar.2025.1670501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。